As per reports, it has been declared that for the time being that the Food and Drug Administration has upheld the approval to a new painkiller. The FDA has asked the Australian Pharmaceutical concerned to provide more detailed information regarding the painkiller.

It has been reported that the FDA has sent a `Complete Response Letter' to the manufacture of the drug, QRxPharma, so as to file more information regarding the safety and effect of the drug, MoxDuo.

Detailed reports regarding the painkiller suggest that it has been prepared using a combination of two popularly prescribed opioids, including morphine and oxycodone. These opioids are widely used to cure mild to severe pain.

The company has claimed that the combination of the opioid drugs will help provide with more significant results and will thereby eliminate side-effects related to the drugs and also will cut-short the demand for a higher dosage.

"We remain confident in MoxDuo as a potential therapeutic option for the millions of patients suffering from moderate to severe acute pain and will continue our efforts to bring this therapy to market", said Dr. John Holoday, QRxPharma's Managing Director and CEO.

The drug, if approved, will be launched in the market in three forms: intravenous, controlled release, and immediate release.